Study on Transcranial Electrostimulation for Pain Relief in OSA Surgery
The investigation of transcranial electrostimulation (TES) for pain relief in obstructive sleep apnea surgery could significantly alter pain management strategies, particularly in a landscape increasingly wary of opioid use. Success in this trial may lead to a shift in treatment protocols and influence product development in the pain management sector.
Phase III
Sleep Disorders / Obstructive Sleep Apnea
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The investigation of transcranial electrostimulation (TES) for pain relief in obstructive sleep apnea surgery could significantly alter pain management strategies, particularly in a landscape increasingly wary of opioid use. Success in this trial may lead to a shift in treatment protocols and influence product development in the pain management sector.
Why it matters
The investigation of transcranial electrostimulation (TES) for pain relief in obstructive sleep apnea surgery could significantly alter pain management strategies, particularly in a landscape increasingly wary of opioid use. Success in this trial may lead to a shift in treatment protocols and influence product development in the pain management sector.
What changed
Trial Update
Analysis
A study is investigating the efficacy of transcranial electrostimulation (TES) for postoperative pain relief in obstructive sleep apnea surgery.
The investigation of transcranial electrostimulation (TES) for pain relief in obstructive sleep apnea surgery could significantly alter pain management strategies, particularly in a landscape increasingly wary of opioid use. Success in this trial may lead to a shift in treatment protocols and influence product development in the pain management sector.
Monitor results of the trial for efficacy data and potential shifts in pain management practices in OSA surgery.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.